title: ÐÑÑÐ¾Ð°Ð½ÑÐ¸ÑÐµÐ»Ð° Ð¿ÑÐ¾ÑÐ¸Ð² Ð½ÐµÐ¹ÑÐ¾ÑÐµÐ½Ð·Ð¸Ð½Ð° Ð² ÐºÑÐ¾Ð²Ð¸ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ Ð±Ð¾Ð»ÐµÐ·Ð½ÑÑ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð°
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: Neurotensin-binding autoantibodies in blood plasma of patients with Parkinsonâs disease
Creators: name: ÐÐ±ÑÐ°Ð»ÑÐ¼Ð¾Ð²Ð°, ÐÐ°ÑÐ³Ð°ÑÐ¸ÑÐ°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2024
Subjects: Ð±Ð¾Ð»ÐµÐ·Ð½Ñ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð°
Ð½ÐµÐ¹ÑÐ¾ÑÐµÐ½Ð·Ð¸Ð½
Ð½ÐµÐ¹ÑÐ¾Ð¿ÐµÐ¿ÑÐ¸Ð´Ñ
Ð°ÑÑÐ¾Ð°Ð½ÑÐ¸ÑÐµÐ»Ð°
Ð¸Ð¼Ð¼ÑÐ½Ð¾ÑÐµÑÐ¼ÐµÐ½ÑÐ½ÑÐ¹ Ð°Ð½Ð°Ð»Ð¸Ð·
Parkinsonâs disease
neurotensin
neuropeptides
autoantibodies
enzyme-linked immunosorbent assay

description: ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° Ð¸Ð·ÑÑÐµÐ½Ð¸Ñ Ð½Ð°Ð»Ð¸ÑÐ¸Ñ Ð² Ð¾ÑÐ³Ð°Ð½Ð¸Ð·Ð¼Ðµ ÑÐµÐ»Ð¾Ð²ÐµÐºÐ° Ð¸Ð¼Ð¼ÑÐ½Ð¾Ð³Ð»Ð¾Ð±ÑÐ»Ð¸Ð½Ð¾Ð², Ð¾Ð±ÑÐ°Ð·ÑÑÑÐ¸Ñ Ñ Ð½ÐµÐ¹ÑÐ¾ÑÐµÐ½Ð·Ð¸Ð½Ð¾Ð¼ Ð±ÐµÐ»ÐºÐ¾Ð²Ð¾-Ð¿ÐµÐ¿ÑÐ¸Ð´Ð½ÑÐµ Ð¼Ð¾Ð´ÑÐ»ÑÑÐ¾ÑÐ½ÑÐµ ÐºÐ¾Ð¼Ð¿Ð»ÐµÐºÑÑ, Ð¸ Ð¸Ñ ÑÐ¾Ð»Ð¸ Ð² ÑÐµÑÐµÐ½Ð¸Ð¸ Ð±Ð¾Ð»ÐµÐ·Ð½Ð¸ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð°, Ð² ÑÐ°ÑÑÐ½Ð¾ÑÑÐ¸ Ð² ÐºÐ°ÑÐµÑÑÐ²Ðµ Ð¿ÐµÑÐµÐºÑÐµÑÑÐ½Ð¾-ÑÐµÐ°ÐºÑÐ¸Ð²Ð½ÑÑ Ð°ÑÑÐ¾Ð°Ð½ÑÐ¸ÑÐµÐ», Ð¿Ð¾ÑÐ²Ð»ÑÑÑÐ¸ÑÑÑ Ð² Ð¾ÑÐ²ÐµÑ Ð½Ð° Ð°Ð½ÑÐ¸Ð³ÐµÐ½Ð½Ð¾Ðµ Ð²Ð¾Ð·Ð´ÐµÐ¹ÑÑÐ²Ð¸Ðµ Ð¼Ð¸ÐºÑÐ¾Ð±Ð½ÑÑ Ð±ÐµÐ»ÐºÐ¾Ð². ÐÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ðµ ÑÑÐ¾Ð²Ð½ÐµÐ¹ IgG Ð¿ÑÐ¾ÑÐ¸Ð² Ð½ÐµÐ¹ÑÐ¾ÑÐµÐ½Ð·Ð¸Ð½Ð° Ð¿ÑÐ¾Ð²Ð¾Ð´Ð¸Ð»Ð¸ Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ Ð¸Ð¼Ð¼ÑÐ½Ð¾ÑÐµÑÐ¼ÐµÐ½ÑÐ½Ð¾Ð³Ð¾ Ð°Ð½Ð°Ð»Ð¸Ð·Ð° Ð½Ð° Ð¾Ð±ÑÐ°Ð·ÑÐ°Ñ Ð¿Ð»Ð°Ð·Ð¼Ñ ÐºÑÐ¾Ð²Ð¸ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ Ð±Ð¾Ð»ÐµÐ·Ð½ÑÑ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð° Ð¸ Ð·Ð´Ð¾ÑÐ¾Ð²ÑÑ Ð´Ð¾Ð±ÑÐ¾Ð²Ð¾Ð»ÑÑÐµÐ². ÐÑÐ» ÑÐ°ÐºÐ¶Ðµ Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½ in silico Ð°Ð½Ð°Ð»Ð¸Ð· Ð½Ð° Ð½Ð°Ð»Ð¸ÑÐ¸Ðµ Ð³Ð¾Ð¼Ð¾Ð»Ð¾Ð³Ð¸Ð¸ Ð¼ÐµÐ¶Ð´Ñ Ð½ÐµÐ¹ÑÐ¾ÑÐµÐ½Ð·Ð¸Ð½Ð¾Ð¼ Ð¸ Ð±ÐµÐ»ÐºÐ°Ð¼Ð¸ Ð¾ÑÐ³Ð°Ð½Ð¸Ð·Ð¼Ð¾Ð² ÑÐµÐ»Ð¾Ð²ÐµÑÐµÑÐºÐ¾Ð¹ Ð¼Ð¸ÐºÑÐ¾Ð±Ð¸Ð¾ÑÑ Ñ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð¸ÐµÐ¼ Ð¾Ð±ÑÐµÐ´Ð¾ÑÑÑÐ¿Ð½Ð¾Ð¹ Ð±ÐµÐ»ÐºÐ¾Ð²Ð¾Ð¹ Ð±Ð°Ð·Ñ Ð´Ð°Ð½Ð½ÑÑ. ÐÐ°Ð¼Ð¸ Ð±ÑÐ»Ð¾ Ð²Ð¿ÐµÑÐ²ÑÐµ Ð¿Ð¾ÐºÐ°Ð·Ð°Ð½Ð¾, ÑÑÐ¾ Ð´Ð»Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ Ð±Ð¾Ð»ÐµÐ·Ð½ÑÑ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð° Ð»ÑÐ±Ð¾Ð³Ð¾ Ð²Ð¾Ð·ÑÐ°ÑÑÐ° Ð¸ Ð¿Ð¾Ð»Ð° ÑÐ°ÑÐ°ÐºÑÐµÑÐ½Ð¾ Ð¼ÐµÐ½ÑÑÐµÐµ ÑÐ¾Ð´ÐµÑÐ¶Ð°Ð½Ð¸Ðµ IgG Ð¿ÑÐ¾ÑÐ¸Ð² Ð½ÐµÐ¹ÑÐ¾ÑÐµÐ½Ð·Ð¸Ð½Ð° Ð² Ð¿Ð»Ð°Ð·Ð¼Ðµ ÐºÑÐ¾Ð²Ð¸, ÑÐµÐ¼ Ð´Ð»Ñ Ð·Ð´Ð¾ÑÐ¾Ð²ÑÑ Ð»ÑÐ´ÐµÐ¹, Ð¸ Ñ Ð¿ÑÐ¾Ð³ÑÐµÑÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð¸ÐµÐ¼ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ñ ÑÑÐ¾Ñ Ð¿Ð¾ÐºÐ°Ð·Ð°ÑÐµÐ»Ñ Ð»Ð¸ÑÑ Ð¿Ð¾Ð½Ð¸Ð¶Ð°ÐµÑÑÑ. ÐÑÐ¸ ÑÑÐ¾Ð¼ ÑÐµÑÐ°Ð¿Ð¸Ñ Ð¿ÑÐ¾ÑÐ¸Ð²Ð¾Ð¿Ð°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð¸ÑÐµÑÐºÐ¸Ð¼Ð¸ Ð»ÐµÐºÐ°ÑÑÑÐ²ÐµÐ½Ð½ÑÐ¼Ð¸ ÑÑÐµÐ´ÑÑÐ²Ð°Ð¼Ð¸ Ð¿Ð¾Ð¼Ð¾Ð³Ð°ÐµÑ Ð¿Ð¾Ð²ÑÑÐ¸ÑÑ ÑÑÐ¾Ð²Ð½Ð¸ Ð½ÐµÐ¹ÑÐ¾ÑÐµÐ½Ð·Ð¸Ð½-ÑÐ²ÑÐ·ÑÐ²Ð°ÑÑÐ¸ÑÑÑ IgG Ð² ÐºÑÐ¾Ð²Ð¸. Ð ÑÐ¾ Ð¶Ðµ Ð²ÑÐµÐ¼Ñ, in silico Ð¸ Ð¼ÐµÑÐ°Ð°Ð½Ð°Ð»Ð¸Ð· Ð¿Ð¾ÐºÐ°Ð·Ð°Ð»Ð¸ Ð½Ð°Ð»Ð¸ÑÐ¸Ðµ Ð±Ð°ÐºÑÐµÑÐ¸Ð¹ Ð¸ Ð²Ð¸ÑÑÑÐ¾Ð², ÐºÐ¾ÑÐ¾ÑÑÐµ ÑÐ¾Ð´ÐµÑÐ¶Ð°Ñ Ð±ÐµÐ»ÐºÐ¸-Ð³Ð¾Ð¼Ð¾Ð»Ð¾Ð³Ð¸ Ð½ÐµÐ¹ÑÐ¾ÑÐµÐ½Ð·Ð¸Ð½Ð° Ð¸ Ð´Ð»Ñ ÐºÐ¾ÑÐ¾ÑÑÑ ÑÐ°ÑÐ°ÐºÑÐµÑÐ½Ð° Ð¸Ð·Ð¼ÐµÐ½ÐµÐ½Ð½Ð°Ñ Ð¿ÑÐµÐ´ÑÑÐ°Ð²Ð»ÐµÐ½Ð½Ð¾ÑÑÑ Ð² Ð¼Ð¸ÐºÑÐ¾Ð±Ð¸Ð¾ÑÐµ ÑÐµÐ»Ð¾Ð²ÐµÐºÐ° Ð¿ÑÐ¸ Ð±Ð¾Ð»ÐµÐ·Ð½Ð¸ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð°. ÐÐ¿Ð¸ÑÐ°ÑÑÑ Ð½Ð° Ð¿Ð¾Ð»ÑÑÐµÐ½Ð½ÑÐµ Ð½Ð°Ð¼Ð¸ ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÑ, Ð¼Ñ Ð¿ÑÐµÐ´Ð¿Ð¾Ð»Ð°Ð³Ð°ÐµÐ¼, ÑÑÐ¾ ÑÐ¾Ð´ÐµÑÐ¶Ð°Ð½Ð¸Ðµ IgG, ÑÐ²ÑÐ·ÑÐ²Ð°ÑÑÐ¸ÑÑÑ Ñ Ð½ÐµÐ¹ÑÐ¾ÑÐµÐ½Ð·Ð¸Ð½Ð¾Ð¼, Ð¼Ð¾Ð¶Ð½Ð¾ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°ÑÑ ÐºÐ°Ðº Ð´Ð¾ÑÑÑÐ¿Ð½ÑÐ¹ Ð¿ÑÐ¾Ð³Ð½Ð¾ÑÑÐ¸ÑÐµÑÐºÐ¸Ð¹ Ð¼Ð°ÑÐºÐµÑ ÑÐµÑÐµÐ½Ð¸Ñ Ð±Ð¾Ð»ÐµÐ·Ð½Ð¸ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð°. Ð¡ÑÐ¾Ð¸Ñ ÑÐ°ÐºÐ¶Ðµ Ð¾ÑÐ¼ÐµÑÐ¸ÑÑ, ÑÑÐ¾ ÑÑÑÐµÑÑÐ²Ð¾Ð²Ð°Ð½Ð¸Ðµ Ð»Ð¸ÑÐµÑÐ°ÑÑÑÐ½ÑÑ Ð´Ð°Ð½Ð½ÑÑ Ð¾ ÑÐ²ÑÐ·Ð¸ Ð¼ÐµÐ¶Ð´Ñ Ð¾Ð±Ð½Ð°ÑÑÐ¶ÐµÐ½Ð½ÑÐ¼Ð¸ in silico Ð¼Ð¸ÐºÑÐ¾Ð¾ÑÐ³Ð°Ð½Ð¸Ð·Ð¼Ð°Ð¼Ð¸ Ð¸ Ð±Ð¾Ð»ÐµÐ·Ð½ÑÑ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð° Ð¼Ð¾Ð¶ÐµÑ Ð³Ð¾Ð²Ð¾ÑÐ¸ÑÑ Ð¾ ÑÐ¾Ð¼, ÑÑÐ¾ Ð½ÐµÐ¾Ð±ÑÐ¾Ð´Ð¸Ð¼Ð¾ Ð´Ð°Ð»ÑÐ½ÐµÐ¹ÑÐµÐµ Ð¸Ð·ÑÑÐµÐ½Ð¸Ðµ Ð²Ð¾Ð¿ÑÐ¾ÑÐ¾Ð², ÑÐ¿Ð¾ÑÐ¾Ð±Ð½Ñ Ð»Ð¸ ÐºÐ°ÐºÐ¸Ðµ-ÑÐ¾ Ð¸Ð· Ð±ÐµÐ»ÐºÐ¾Ð²-Ð³Ð¾Ð¼Ð¾Ð»Ð¾Ð³Ð¾Ð² ÑÑÐ¸Ð¼ÑÐ»Ð¸ÑÐ¾Ð²Ð°ÑÑ Ð¾Ð±ÑÐ°Ð·Ð¾Ð²Ð°Ð½Ð¸Ðµ IgG, Ð¿ÐµÑÐµÐºÑÐµÑÑÐ½Ð¾ ÑÐµÐ°Ð³Ð¸ÑÑÑÑÐ¸Ñ Ñ Ð½ÐµÐ¹ÑÐ¾ÑÐµÐ½Ð·Ð¸Ð½Ð¾Ð¼, Ð¸ Ð¼Ð¾Ð³ÑÑ Ð»Ð¸ ÑÐ°ÐºÐ¸Ðµ IgG ÑÑÐ¸Ð»Ð¸Ð²Ð°ÑÑ Ð½ÐµÐ¹ÑÐ¾Ð¿ÑÐ¾ÑÐµÐºÑÐ¾ÑÐ½ÑÐµ ÑÑÑÐµÐºÑÑ Ð´Ð°Ð½Ð½Ð¾Ð³Ð¾ Ð½ÐµÐ¹ÑÐ¾Ð¿ÐµÐ¿ÑÐ¸Ð´Ð° Ð¿ÑÐ¸ Ð±Ð¾Ð»ÐµÐ·Ð½Ð¸ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð°.
description: The given work is devoted to identifying the presence of immunoglobulins that circulate bound to neurotensin in humans, and studying the involvement of these IgGs in the course of Parkinsonâs disease, in particular, as cross-reactive autoantibodies produced in response to antigenic stimulation by microbial proteins. The study of neurotensin-binding IgG levels was carried out using enzyme-linked immunosorbent assay on plasma samples of Parkinsonâs disease patients and healthy volunteers. An in silico sequence homology analysis between human neurotensin and microbial proteins was also performed, using a public protein database. We have for the first time found that, compared to healthy controls, Parkinsonâs disease patients of any age or gender are characterized by lower neurotensin-binding IgG plasma levels, which only decrease with the progression of the disease. It also turns out that anti-parkinsonian drug therapy leads to an increase in plasma levels of neurotensin-binding IgGs. At the same time, in silico and meta-analysis showed the existence of microbial proteins, homologous to neurotensin, as well as the altered presence of their original bacteria and viruses in gut microbiota of patients with Parkinsonâs disease. Based on our results, we suggest that the plasma levels of neurotensin-binding IgGs can be used as an accessible prognostic marker for the course of Parkinsonâs disease. It is also worth mentioning that since there exists data that shows the link between Parkinsonâs disease and the microorganisms that we found in silico, further studies are needed to determine if any of the detected homologues can stimulate production of neurotensin cross-reactive IgGs and whether such IgGs may enhance the neuroprotective effects of this neuropeptide in Parkinsonâs disease.